Pay in 4 interest-free payments of $5.55 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
In a randomized, placebo-controlled study of 495 patients with intermittent claudication, 2 g/day of propionyl-L-carnitine for 12 months significantly increased maximal walking distance and the distance walked prior to the onset of claudication in patients whose initial maximal walking distance was less than 250 meters (m), but no effect was seen in patients who had an initial maximal walking distance greater than 250 m (65)
Asian, Hispanic, and Black patients had lower risks) Medicaid eligibility (HR = 1.18) Rural residence (HR = 1.08) Diabetic retinopathy (HR = 1.66) Obstructive sleep apnea (HR = 1.08) Chronic kidney disease (HR = 1.12) Amiodarone use (HR = 1.77) Current insulin use (HR = 1.43) The median time from GLP-1 RA initiation to NAION diagnosis was 3.3 years
The improvement in insulin sensitivity that accompanies GLP-1 therapy provides an additional anti-inflammatory pathway
Published 2022 Jan 4
